Dr. Sambrook's concern was the effect of bisphosphonates on fetal development. The patient was not pregnant, but might have become so intentionally or unintentionally. Bisphosphonates are classified as pregnancy category C drugs by the Food and Drug Administration, meaning that they are contraindicated in pregnancy.
One approach to managing this patient is to simply watch her and measure BMD in 12 months. Another is to use a bisphosphonate in conjunction with vitamin D and calcium supplementation. Risedronate might be the better choice, given its quicker onset and offset of action, he said.
“As long as she stayed on prednisone, I might not be as aggressive as with postmenopausal women,” Dr. Sambrook noted. If the prednisone dose was decreased, he said that he might consider stopping bisphosphonate treatment.
Dr. Lane and Dr. Sambrook both reported financial relationships with several pharmaceutical companies.
A whole-body dual-energy x-ray absorptiometry scan can provide information on total and regional BMD (left) and body composition (fat, muscle mass).
Source ©Elsevier